Amanta Healthcare Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, demonstrating consistent revenue momentum and strong profitability growth. The pharmaceutical company, specializing in sterile liquid products, reported sustained performance across key financial metrics during the reporting period.

Q3FY26 Financial Performance

The company delivered solid quarterly results with revenue growth driven by steady demand and volume expansion. Operating discipline helped maintain healthy EBITDA margins despite competitive market conditions.

Nine-Month FY26 Results Show Strong Momentum

The nine-month performance highlighted the company's robust execution capabilities and improving earnings quality. PAT margins expanded significantly, reflecting operational leverage and effective cost management strategies.

Management Commentary on Performance

Bhavesh Patel, Chairman & Managing Director, highlighted the company's resilient business model and focused growth initiatives. He emphasized that the company undertook strategic initiatives during the nine-month period to support future growth, which are expected to reflect in performance in coming quarters.

The management outlined key strategic priorities including:

• Wallet share expansion in complex therapies
• Scaling high-margin SteriPort and SVP capacities
• Structural cost optimization through green energy initiatives
• Positioning for accelerated growth from Q4 onwards

Company Profile and Business Focus

Amanta Healthcare operates as a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including large and small volume parenteral products. The company utilizes advanced Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding technologies to serve six therapeutic segments.

The company's product portfolio includes:

• IV fluids and diluents
• Ophthalmic and respiratory care products
• Irrigation solutions
• Container volumes ranging from 2 ml to 1000 ml

With over 30 years of industry experience, the management team continues to drive operational excellence and strategic growth initiatives across the organization.

Amanta Healthcare Limited has announced changes in its senior management personnel structure, with the Board of Directors approving key appointments and removals effective February 10, 2026. The pharmaceutical company has formally communicated these changes to stock exchanges in compliance with regulatory requirements.

Board Approval and Regulatory Compliance

The Board of Directors of Amanta Healthcare Limited, acting on recommendations from the Nomination and Remuneration Committee, approved the senior management changes on February 10, 2026. The company has notified both BSE Limited (Scrip Code: 544502) and National Stock Exchange of India Limited (Trading Symbol: AMANTA) about these personnel changes pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Senior Management Personnel Changes

The company announced two significant changes to its senior management team:

Profile of New Senior Management Personnel

Shri Urmil Oza brings substantial experience and expertise to his role as Senior Management Personnel. His professional background includes:

Key Responsibilities and Expertise

Urmil Oza's extensive experience encompasses multiple critical areas within the organization:

• Production Engineering: Leading production engineering operations and utility equipment management
• Project Management: Overseeing project activities and technical procurement processes
• Vendor Relations: Managing all plant and utility side vendor communications
• Equipment Management: Handling utility and plant equipment maintenance and operational management on a routine basis
• Regulatory Compliance: Managing all government-related documentation and compliance requirements

Corporate Governance

The announcement was signed by Nikhita Dinodia, Company Secretary and Compliance Officer (Membership No. 53362), ensuring proper corporate governance protocols. The company has requested both stock exchanges to take note of these changes in their records, maintaining transparency with stakeholders and regulatory bodies.